DB15472ExperimentalProtein Based Therapies
According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload." It is being...
- Also known as
- anti-HER2 x HER2 ADC
- Code names
- ZW-49
Resolves to
Compound
What you can answer from here — as of March 06, 2025
Which companies are running trials of Zanidatamab zovodotin, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account